Story perspectives
Sanofi's Efdoralprin Alfa Shows Promising Results for Emphysema
10/23/2025
39 8
1 of 1
Story summary
- Sanofi SA announced topline results from the ElevAATe phase 2 study of efdoralprin alfa for alpha-1 antitrypsin deficiency–related emphysema.
- The study met all primary and key secondary endpoints when given every three or four weeks.
- Efdoralprin alfa significantly increased functional alpha-1 antitrypsin (AAT) levels versus weekly plasma-derived therapy.
- Sanofi plans to present the findings at a medical meeting and consult regulators on next steps.
